Global health company M42 has announced a strategic investment and partnership with longevity biotech Juvenescence.   The partnership will focus on identifying and developing a pipeline of AI-enabled therapeutics to extend healthy lifespan and advance the treatment of life-threatening diseases. The partnership will leverage M42’s expertise in genomics, biobanking and clinical trial infrastructure alongside Juvenescence’s AI-enabled […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!